Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans - PubMed (original) (raw)
Clinical Trial
doi: 10.1038/nm881. Epub 2003 May 25.
William H H Reece, Vasee S Moorthy, Daniel Webster, Susanna Dunachie, Geoff Butcher, Jenni M Vuola, Tom J Blanchard, Philip Gothard, Kate Watkins, Carolyn M Hannan, Simone Everaere, Karen Brown, Kent E Kester, James Cummings, Jackie Williams, D Gray Heppner, Ansar Pathan, Katie Flanagan, Nirmalan Arulanantham, Mark T M Roberts, Michael Roy, Geoffrey L Smith, Joerg Schneider, Tim Peto, Robert E Sinden, Sarah C Gilbert, Adrian V S Hill
Affiliations
- PMID: 12766765
- DOI: 10.1038/nm881
Clinical Trial
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
Samuel J McConkey et al. Nat Med. 2003 Jun.
Abstract
In animals, effective immune responses against malignancies and against several infectious pathogens, including malaria, are mediated by T cells. Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high frequencies of interferon (IFN)-gamma-secreting, antigen-specific T-cell responses in humans to a pre-erythrocytic malaria antigen, thrombospondin-related adhesion protein (TRAP). These responses are five- to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia after sporozoite challenge with a different strain of Plasmodium falciparum. Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans.
Comment in
- Prime boost vaccines power up in people.
Robinson HL. Robinson HL. Nat Med. 2003 Jun;9(6):642-3. doi: 10.1038/nm0603-642. Nat Med. 2003. PMID: 12778154 No abstract available.
Similar articles
- Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV. Moorthy VS, et al. J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24. J Infect Dis. 2004. PMID: 15181568 Clinical Trial. - A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV. Prieur E, et al. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. doi: 10.1073/pnas.0307158101. Epub 2003 Dec 23. Proc Natl Acad Sci U S A. 2004. PMID: 14694197 Free PMC article. - Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
Moore AC, Hill AV. Moore AC, et al. Immunol Rev. 2004 Jun;199:126-43. doi: 10.1111/j.0105-2896.2004.00138.x. Immunol Rev. 2004. PMID: 15233731 Review. - DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
Hill AV, Reece W, Gothard P, Moorthy V, Roberts M, Flanagan K, Plebanski M, Hannan C, Hu JT, Anderson R, Degano P, Schneider J, Prieur E, Sheu E, Gilbert SC. Hill AV, et al. Dev Biol (Basel). 2000;104:171-9. Dev Biol (Basel). 2000. PMID: 11713817 Review.
Cited by
- TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice.
Zhang X, Chen Y, Wang S, Zhong L, Xiang Z, Zhang X, Zhang S, Zhou X, Zhang W, Zhou Y, Zhang Q, Liang J, Luo Y, Wang Y, Chen L, Ye X, Feng Q, Zeng MS, Liu Y, Zeng YX, Shao Y, Xu M. Zhang X, et al. Emerg Microbes Infect. 2024 Dec;13(1):2412640. doi: 10.1080/22221751.2024.2412640. Epub 2024 Oct 13. Emerg Microbes Infect. 2024. PMID: 39387189 Free PMC article. - Plasmodium vivax vaccine: What is the best way to go?
da Veiga GTS, Moriggi MR, Vettorazzi JF, Müller-Santos M, Albrecht L. da Veiga GTS, et al. Front Immunol. 2023 Jan 16;13:910236. doi: 10.3389/fimmu.2022.910236. eCollection 2022. Front Immunol. 2023. PMID: 36726991 Free PMC article. Review. - How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells.
Garnica M, Aiello A, Ligotti ME, Accardi G, Arasanz H, Bocanegra A, Blanco E, Calabrò A, Chocarro L, Echaide M, Kochan G, Fernandez-Rubio L, Ramos P, Pojero F, Zareian N, Piñeiro-Hermida S, Farzaneh F, Candore G, Caruso C, Escors D. Garnica M, et al. Int J Mol Sci. 2022 Aug 29;23(17):9797. doi: 10.3390/ijms23179797. Int J Mol Sci. 2022. PMID: 36077216 Free PMC article. Review. - Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.
Kibwana E, Kapulu M, Bejon P. Kibwana E, et al. Curr Top Microbiol Immunol. 2024;445:337-365. doi: 10.1007/82_2022_256. Curr Top Microbiol Immunol. 2024. PMID: 35704094 Free PMC article. Review. - Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity.
Sluder AE, Raju Paul S, Moise L, Dold C, Richard G, Silva-Reyes L, Baeten LA, Scholzen A, Reeves PM, Pollard AJ, Garritsen A, Bowen RA, De Groot AS, Rollier C, Poznansky MC. Sluder AE, et al. Front Immunol. 2022 May 16;13:901372. doi: 10.3389/fimmu.2022.901372. eCollection 2022. Front Immunol. 2022. PMID: 35651616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources